C-IDDApartial reprogramming, senolytic polyphenols, longevity diagnostics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
199 Biotechnologies states that cancer is fundamentally driven by epigenetic alterations and that existing treatments are inadequate because they focus on killing cells rather than reprogramming them, which contributes to resistance and recurrence. The company believes cancer-specific epigenetic reprogramming can restore more normal cellular function, induce natural senescent apoptosis in cancer cells, and provide a first-in-class therapeutic approach, with an initial focus on hard-to-treat brain cancers.
Source199 Biotechnologies states that ageing can be slowed, halted, and reversed through staged therapeutic approaches: preventive measures to delay chronic disease and improve healthspan and lifespan, combination therapies that target multiple hallmarks of ageing to stop age-related decline, and cellular reprogramming that restores youthful epigenetic information to reverse cellular ageing. The company frames this as part of a broader goal to extend maximum lifespan to 199 and beyond.
Source199 Biotechnologies states that it develops therapies intended to slow, halt, and reverse ageing, reflecting a belief that ageing can be therapeutically targeted and modified to extend both healthspan and lifespan, with an aspirational goal of reaching 199 years and beyond.
Source